kidney disease

chronic kidney disease money
Biotech

Akebia promises $12M for Q32’s rare kidney disease candidate

Akebia has struck a deal for Q32's complement inhibitor ADX-097, bagging an asset that forms the centerpiece of its new rare kidney disease pipeline.
Nick Paul Taylor Dec 1, 2025 9:45pm
Uptal Patel

Biogen returns to its roots with a West Coast immunology outpost

Nov 18, 2025 12:25pm
scissor cutting rope

AbbVie to end Calico collab, lay off scientists: Stat

Nov 13, 2025 3:59pm
Human kidney anatomy

Otsuka's kidney disease drug halves UPCR levels in ph. 3 study

Jun 6, 2025 6:26am
MA strategy deal block push come together form

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

May 1, 2025 10:59am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

Apr 30, 2025 9:30am